Difficulties and challenges in the development of precision medicine

The rapid development of precision medicine is introducing a new era of significance in medicine. However, attaining precision medicine is an ambitious goal that is bound to encounter some challenges. Here, we have put forward some difficulties or questions that should be addressed by the progress in this field. The proposed issues include the long road to precision medicine for all types of diseases as the unknown domains of the human genome hinder the development of precision medicine. The challenges in the acquisition and analysis of large amounts of omics data, including difficulties in the establishment of a library of biological samples and large‐scale data analysis, as well as the challenges of informed consent and medical ethics in precision medicine, must be overcome to attain the goals of precision medicine. To date, precision medicine programs have accomplished many preliminary achievements and will help to drive a dramatic revolution in clinical practices for the medical community. Through these advances, the diagnosis and treatment of many diseases will achieve many breakthroughs. This project is just beginning and requires a great deal of time and money. Precision medicine also requires extensive collaboration. Ultimately, these difficulties can be overcome. We should realize that precision medicine is good for patients, but there is still a long way to go.

[1]  M. Rothstein Review for "Difficulties and challenges in the development of precision medicine" , 2018 .

[2]  D. Cooper,et al.  Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy. , 2017, Omics : a journal of integrative biology.

[3]  P. Sankar,et al.  The Precision Medicine Initiative’s All of Us Research Program: an agenda for research on its ethical, legal, and social issues , 2016, Genetics in Medicine.

[4]  Elisa Michelini,et al.  Advanced bioanalytics for precision medicine , 2017, Analytical and Bioanalytical Chemistry.

[5]  Kai Ye,et al.  Precision Medicine: What Challenges Are We Facing? , 2016, Genom. Proteom. Bioinform..

[6]  Abdellah Tebani,et al.  Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations , 2016, International journal of molecular sciences.

[7]  Stephanie Devaney,et al.  A Survey of U.S Adults’ Opinions about Conduct of a Nationwide Precision Medicine Initiative® Cohort Study of Genes and Environment , 2016, PloS one.

[8]  C. Harris,et al.  Biomarker development in the precision medicine era: lung cancer as a case study , 2016, Nature Reviews Cancer.

[9]  Precision medicine , 2016, Healthcare management forum.

[10]  Vence L Bonham,et al.  Will Precision Medicine Move Us beyond Race? , 2016, The New England journal of medicine.

[11]  David Cyranoski,et al.  China embraces precision medicine on a massive scale , 2016, Nature.

[12]  R. Pazdur,et al.  Next-Generation Sequencing in Oncology in the Era of Precision Medicine. , 2016, JAMA oncology.

[13]  E. Knudsen,et al.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. , 2016, Gastroenterology.

[14]  Gary W Procop,et al.  Prospective Clinical Study of Precision Oncology in Solid Tumors. , 2015, Journal of the National Cancer Institute.

[15]  Muin J Khoury,et al.  Planning for the Future of Epidemiology in the Era of Big Data and Precision Medicine. , 2015, American journal of epidemiology.

[16]  Y. Joly,et al.  Privacy and Biobanking in China: A Case of Policy in Transition , 2015, Journal of Law, Medicine & Ethics.

[17]  Keith R. Yamamoto,et al.  Precision medicine: Beyond the inflection point , 2015, Science Translational Medicine.

[18]  Denis Horgan,et al.  Is precision medicine the route to a healthy world? , 2015, The Lancet.

[19]  Jonathan S Berg,et al.  Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. , 2015, American journal of human genetics.

[20]  S. Jaffe Planning for US Precision Medicine Initiative underway , 2015, The Lancet.

[21]  D. Longo,et al.  Precision medicine--personalized, problematic, and promising. , 2015, The New England journal of medicine.

[22]  Euan A Ashley,et al.  The precision medicine initiative: a new national effort. , 2015, JAMA.

[23]  S. Barlas Precision medicine initiative aims for a new generation of diagnostics and treatments: but is the promise of genetic targeting overinflated? , 2015, P & T : a peer-reviewed journal for formulary management.

[24]  Alexey M. Kozlov,et al.  ExaML version 3: a tool for phylogenomic analyses on supercomputers , 2015, Bioinform..

[25]  Eric S. Lander,et al.  Cutting the Gordian helix--regulating genomic testing in the era of precision medicine. , 2015, The New England journal of medicine.

[26]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[27]  M. Ritchie,et al.  Methods of integrating data to uncover genotype–phenotype interactions , 2015, Nature Reviews Genetics.

[28]  Yogesh K. Dwivedi,et al.  Noncoding RNAs and neurobehavioral mechanisms in psychiatric disease , 2015, Molecular Psychiatry.

[29]  Sara Reardon Precision-medicine plan raises hopes. , 2015, Nature.

[30]  Jyotishman Pathak,et al.  Empowering personalized medicine with big data and semantic web technology: Promises, challenges, and use cases , 2014, 2014 IEEE International Conference on Big Data (Big Data).

[31]  Marek S. Wiewiórka,et al.  SparkSeq: fast, scalable and cloud-ready tool for the interactive genomic data analysis with nucleotide precision , 2014, Bioinform..

[32]  Ian T. Foster,et al.  Supercomputing for the parallelization of whole genome analysis , 2014, Bioinform..

[33]  Benjamin J. Raphael,et al.  Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine , 2014, Genome Medicine.

[34]  Lisa McShane,et al.  National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[35]  B. S. Muddukrishna,et al.  Informed consent: Issues and challenges , 2013, Journal of advanced pharmaceutical technology & research.

[36]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[37]  J. Barrett,et al.  How next-generation sequencing is transforming complex disease genetics. , 2013, Trends in genetics : TIG.

[38]  Rui Chen,et al.  Promise of personalized omics to precision medicine , 2013, Wiley interdisciplinary reviews. Systems biology and medicine.

[39]  Muin J Khoury,et al.  A population approach to precision medicine. , 2012, American journal of preventive medicine.

[40]  J. Gray,et al.  Omics and therapy – A basis for precision medicine , 2012, Molecular oncology.

[41]  J. Rinn,et al.  Modular regulatory principles of large non-coding RNAs , 2012, Nature.

[42]  M. Batzer,et al.  Repetitive Elements May Comprise Over Two-Thirds of the Human Genome , 2011, PLoS genetics.

[43]  Kevin C. Dorff,et al.  The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models , 2010, Nature Biotechnology.

[44]  F. Collins,et al.  The path to personalized medicine. , 2010, The New England journal of medicine.

[45]  C. Gravlee How race becomes biology: embodiment of social inequality. , 2009, American journal of physical anthropology.

[46]  I. Goodhead,et al.  Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution , 2008, Nature.